BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cue Biopharma , Inc. (Nasdaq: NASDAQ:), a clinical-stage biopharmaceutical firm creating a novel class of therapeutic biologics to selectively have interaction and modulate disease-specific T cells, at this time introduced the pricing of an underwritten public providing of (i) 11,564,401 shares of its widespread inventory and accompanying widespread inventory warrants to buy an combination of two,891,100 shares of widespread inventory and, (ii) to sure buyers in lieu of widespread inventory, pre-funded warrants to buy 12,435,599 shares of widespread inventory and accompanying widespread inventory warrants to buy an combination of three,108,900 shares of widespread inventory. Every share of widespread inventory and accompanying widespread inventory warrant are being bought collectively at a mixed public providing worth of $0.50, and every pre-funded warrant and accompanying widespread inventory warrant are being bought collectively at a mixed public providing worth of $0.499. The combination gross proceeds of the providing are anticipated to be roughly $12.0 million, earlier than deducting underwriting reductions and commissions and different providing bills. Every pre-funded warrant can have an train worth of $0.001 per share, shall be exercisable instantly and shall be exercisable till all the pre-funded warrants are exercised in full. Every widespread inventory warrant can have an train worth of $0.50 per share, shall be exercisable instantly and can expire 5 years from the date of issuance. The providing is predicted to shut on or about September 30, 2024, topic to satisfaction of customary closing circumstances. The entire securities are being supplied by Cue Biopharma.
Oppenheimer & Co. Inc. is performing as sole book-running supervisor for the providing. Newbridge Securities Company is performing as co-manager for the providing.
A shelf registration assertion on Type S-3 (File No. 333-271786) regarding the securities to be supplied within the public providing was filed with the Securities and Alternate Fee (the SEC) on Could 9, 2023 and declared efficient on Could 26, 2023. The providing was made solely by way of a prospectus complement and accompanying prospectus that type part of the registration assertion. A preliminary prospectus complement regarding and describing the phrases of the providing has been filed with the SEC and could also be obtained at no cost by visiting the SEC’s web site at www.sec.gov. A last prospectus complement regarding the providing shall be filed with the SEC. When obtainable, copies of the preliminary prospectus complement and last prospectus complement regarding the providing may additionally be obtained by contacting: Oppenheimer & Co. Inc., Consideration: Syndicate Prospectus Division, 85 Broad Road, twenty sixth Ground, New York, New York 10004, by phone at (212) 667-8055, or by electronic mail at [email protected].
This press launch doesn’t represent a suggestion to promote, or a solicitation of a suggestion to purchase these securities, nor shall there be any sale of, these securities in any state or jurisdiction through which such provide, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical firm, is creating a novel class of injectable biologics to selectively have interaction and modulate disease-specific T cells immediately throughout the affected person’s physique. The corporate’s proprietary platform, Immuno-STAT™ (Selective Focusing on and Alteration of T cells), and biologics are designed to harness the healing potential of the physique’s intrinsic immune system by way of the selective modulation of disease-specific T cells with out the adversarial results of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we’re led by an skilled administration workforce and unbiased Board of Administrators with deep experience in immunology and immuno-oncology in addition to the design and scientific improvement of protein biologics.
Cautionary Be aware Relating to Ahead-Trying Statements
This press launch comprises forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995. Such forward-looking statements embrace, however aren’t restricted to, these relating to: the proposed public providing, together with the satisfaction of customary closing circumstances regarding the providing and the anticipated closing of the general public providing. Ahead-looking statements, that are based mostly on sure assumptions and describe the corporate’s future plans, methods and expectations, can usually be recognized by means of forward-looking phrases resembling anticipate, imagine, proceed, might, estimate, count on, aim, intend, could, plan, potential, predict, mission, search, ought to, goal, will, would or different comparable phrases, though not all forward-looking statements include these figuring out phrases.
Cue Biopharma could not truly obtain the plans, intentions or expectations disclosed in its forward-looking statements, and you shouldn’t place undue reliance on its forward-looking statements. Precise outcomes or occasions might differ materially from the plans, intentions and expectations disclosed within the forward-looking statements Cue Biopharma makes because of numerous dangers and uncertainties, together with however not restricted to the satisfaction of customary closing circumstances associated to the general public providing, Cue Biopharma’s restricted working historical past, restricted money and a historical past of losses, Cue Biopharma’s potential to attain profitability, potential setbacks in Cue Biopharma’s analysis and improvement efforts together with destructive or inconclusive outcomes from its preclinical research or scientific trials or Cue Biopharma’s potential to duplicate in later scientific trials optimistic outcomes present in preclinical research and early-stage scientific trials of its product candidates and different dangers and uncertainties described within the Danger Components and Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations sections of Cue Biopharma’s most not too long ago filed Annual Report on Type 10-Okay and any subsequently filed Quarterly Stories on Type 10-Q. Any forward-looking assertion made by Cue Biopharma on this press launch relies solely on info at the moment obtainable to Cue Biopharma and speaks solely as of the date on which it’s made. Cue Biopharma undertakes no obligation to publicly replace any forward-looking assertion, whether or not written or oral, that could be made every so often, whether or not because of new info, future developments or in any other case.
Investor Contact
Marie Campinell
Senior Director, Company Communications
Cue Biopharma, Inc.
[email protected]
Media Contact
Jonathan Pappas
LifeSci Communications
[email protected]
Supply: Cue Biopharma, Inc.